Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Epilepsia ; 60(5): 830-844, 2019 05.
Article in English | MEDLINE | ID: mdl-30968951

ABSTRACT

OBJECTIVE: Pathogenic variants in SCN8A have been associated with a wide spectrum of epilepsy phenotypes, ranging from benign familial infantile seizures (BFIS) to epileptic encephalopathies with variable severity. Furthermore, a few patients with intellectual disability (ID) or movement disorders without epilepsy have been reported. The vast majority of the published SCN8A patients suffer from severe developmental and epileptic encephalopathy (DEE). In this study, we aimed to provide further insight on the spectrum of milder SCN8A-related epilepsies. METHODS: A cohort of 1095 patients were screened using a next generation sequencing panel. Further patients were ascertained from a network of epilepsy genetics clinics. Patients with severe DEE and BFIS were excluded from the study. RESULTS: We found 36 probands who presented with an SCN8A-related epilepsy and normal intellect (33%) or mild (61%) to moderate ID (6%). All patients presented with epilepsy between age 1.5 months and 7 years (mean = 13.6 months), and 58% of these became seizure-free, two-thirds on monotherapy. Neurological disturbances included ataxia (28%) and hypotonia (19%) as the most prominent features. Interictal electroencephalogram was normal in 41%. Several recurrent variants were observed, including Ile763Val, Val891Met, Gly1475Arg, Gly1483Lys, Phe1588Leu, Arg1617Gln, Ala1650Val/Thr, Arg1872Gln, and Asn1877Ser. SIGNIFICANCE: With this study, we explore the electroclinical features of an intermediate SCN8A-related epilepsy with mild cognitive impairment, which is for the majority a treatable epilepsy.


Subject(s)
Epilepsy/genetics , Mutation, Missense , NAV1.6 Voltage-Gated Sodium Channel/genetics , Anticonvulsants/therapeutic use , Ataxia/genetics , Child , Child, Preschool , Cognitive Dysfunction/genetics , Electroencephalography , Epilepsy/drug therapy , Epilepsy/physiopathology , Genetic Testing , High-Throughput Nucleotide Sequencing , Humans , Infant , Intellectual Disability/genetics , Language Development Disorders/genetics , Movement Disorders/genetics , Muscle Hypotonia/genetics , Pedigree , Severity of Illness Index
2.
Epilepsia ; 56(12): e203-8, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26537434

ABSTRACT

The first mutations identified in SLC2A1, encoding the glucose transporter type 1 (GLUT1) protein of the blood-brain barrier, were associated with severe epileptic encephalopathy. Recently, dominant SLC2A1 mutations were found in rare autosomal dominant families with various forms of epilepsy including early onset absence epilepsy (EOAE), myoclonic astatic epilepsy (MAE), and genetic generalized epilepsy (GGE). Our study aimed to investigate the possible role of SLC2A1 in various forms of epilepsy including MAE and absence epilepsy with early onset. We also aimed to estimate the frequency of GLUT1 deficiency syndrome in the Danish population. One hundred twenty patients with MAE, 50 patients with absence epilepsy, and 37 patients with unselected epilepsies, intellectual disability (ID), and/or various movement disorders were screened for mutations in SLC2A1. Mutations in SLC2A1 were detected in 5 (10%) of 50 patients with absence epilepsy, and in one (2.7%) of 37 patient with unselected epilepsies, ID, and/or various movement disorders. None of the 120 MAE patients harbored SLC2A1 mutations. We estimated the frequency of SLC2A1 mutations in the Danish population to be approximately 1:83,000. Our study confirmed the role of SLC2A1 mutations in absence epilepsy with early onset. However, our study failed to support the notion that SLC2A1 aberrations are a cause of MAE without associated features such as movement disorders.


Subject(s)
Carbohydrate Metabolism, Inborn Errors/epidemiology , Epilepsies, Myoclonic/genetics , Epilepsy, Absence/genetics , Glucose Transporter Type 1/genetics , Monosaccharide Transport Proteins/deficiency , Carbohydrate Metabolism, Inborn Errors/genetics , Child, Preschool , Denmark/epidemiology , Epilepsy, Generalized/genetics , Glucose Transporter Type 1/deficiency , Glucose Transporter Type 1/physiology , Humans , Infant , Monosaccharide Transport Proteins/genetics , Mutation , Syndrome
3.
Neurology ; 88(5): 483-492, 2017 01 31.
Article in English | MEDLINE | ID: mdl-28053010

ABSTRACT

OBJECTIVE: To examine the role of mutations in GABRB3 encoding the ß3 subunit of the GABAA receptor in individual patients with epilepsy with regard to causality, the spectrum of genetic variants, their pathophysiology, and associated phenotypes. METHODS: We performed massive parallel sequencing of GABRB3 in 416 patients with a range of epileptic encephalopathies and childhood-onset epilepsies and recruited additional patients with epilepsy with GABRB3 mutations from other research and diagnostic programs. RESULTS: We identified 22 patients with heterozygous mutations in GABRB3, including 3 probands from multiplex families. The phenotypic spectrum of the mutation carriers ranged from simple febrile seizures, genetic epilepsies with febrile seizures plus, and epilepsy with myoclonic-atonic seizures to West syndrome and other types of severe, early-onset epileptic encephalopathies. Electrophysiologic analysis of 7 mutations in Xenopus laevis oocytes, using coexpression of wild-type or mutant ß3, together with α5 and γ2s subunits and an automated 2-microelectrode voltage-clamp system, revealed reduced GABA-induced current amplitudes or GABA sensitivity for 5 of 7 mutations. CONCLUSIONS: Our results indicate that GABRB3 mutations are associated with a broad phenotypic spectrum of epilepsies and that reduced receptor function causing GABAergic disinhibition represents the relevant disease mechanism.


Subject(s)
Epilepsy/genetics , Mutation , Receptors, GABA-A/genetics , Animals , Automation, Laboratory , Child , Child, Preschool , Cohort Studies , Epilepsy/physiopathology , Female , Heterozygote , High-Throughput Nucleotide Sequencing , Humans , Infant , Infant, Newborn , Male , Membrane Potentials/physiology , Oocytes , Patch-Clamp Techniques , Phenotype , Receptors, GABA-A/metabolism , Xenopus laevis
5.
Ugeskr Laeger ; 171(4): 221-5, 2009 Jan 19.
Article in Danish | MEDLINE | ID: mdl-19174036

ABSTRACT

INTRODUCTION: Treatment with valproate is associated with an increased risk of teratogenicity compared to other antiepileptic drugs and can cause a complex of serious symptoms usually referred to as "foetal valproate symdrome" which is characterised by major and minor malformations in association with developmental delay. This paper aims to give attention to the syndrome through four case descriptions. Furthermore, possible risk factors and the use of the mutation 677C-T as a risk marker are discussed. MATERIAL AND METHODS: Nine developmentally retarded children from a parent group, born of mothers who were treated with valproate during pregnancy, were neuropediatrically and neuropsychologically examined in a non-acute setting. The mothers were screened for the 677C-T mutation. RESULTS: Four of seven examined children fulfilled the criteria for foetal valproate syndrome. Only one of the four mothers was heterozygote for the 677C-T mutation (CT, n = 1/4) and none of the mothers were homozygote (TT, n = 0/4) CONCLUSION: The foetal valproate syndrome is a complex of symptoms which is probably underdiagnosed and should be considered in the diagnostic evaluation program for children with developmental delay who are born of mothers with epilepsy. The 677C-T mutation does not seem to be a useful genetic marker of this syndrome.


Subject(s)
Abnormalities, Drug-Induced/etiology , Anticonvulsants/adverse effects , Developmental Disabilities/chemically induced , Valproic Acid/adverse effects , Child , Child, Preschool , Epilepsy/drug therapy , Female , Genetic Markers/genetics , Humans , Male , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Pregnancy , Pregnancy Complications/drug therapy , Risk Factors , Syndrome
6.
Ugeskr Laeger ; 170(20): 1740-3, 2008 May 12.
Article in Danish | MEDLINE | ID: mdl-18489889

ABSTRACT

INTRODUCTION: Commotio cerebri often occurs in children. The purpose of this study is to illustrate how children with commotio cerebri are treated at paediatric departments in Denmark MATERIALS AND METHODS: A questionnaire regarding visitation, admission, observation, discharge and follow-up of children with commotio cerebri as well as department guidelines was mailed to Danish paediatric departments in the period March-September 2006. RESULTS: Children are often initially treated in the emergency room and admitted to a paediatric department if there is a need for observation. The observation period varies within 24 hours. In most departments observation is standardized, for instance according to the Glasgow Coma Scale. Oral information at discharge is always given, whereas written information about symptoms of commotio cerebri and possible late complications are given by 58% of paediatric departments. Follow-up of the worse cases of commotio cerebri is scheduled by 68% of paediatric departments. Most departments have guidelines for the treatment of patients with commotio cerebri. CONCLUSION: There are differences regarding the period of observation for admitted children with commotio cerebri. Oral and written information for parents about deterioration symptoms and possible late complications is recommended along with a statement in the journal of each patient regarding the need for a follow-up. A broader dialogue between the different groups of doctors who treat children with commotio cerebri is recommended.


Subject(s)
Brain Concussion/therapy , Brain Concussion/diagnosis , Child , Child, Preschool , Denmark , Follow-Up Studies , Glasgow Coma Scale , Guideline Adherence , Humans , Infant , Patient Discharge , Patient Education as Topic , Practice Guidelines as Topic , Practice Patterns, Physicians' , Surveys and Questionnaires
7.
Ugeskr Laeger ; 170(15): 1239-42, 2008 Apr 07.
Article in Danish | MEDLINE | ID: mdl-18433580

ABSTRACT

A list of practical advice and examples are given based on the literature. E-learning with cliffhanger text-cases can activate prior knowledge, and selected examination skills can be trained with simulated patients. Patient video recordings can be used to train clinical reasoning skills, including pattern recognition and hypothetic-deductive approaches. Interactive approaches, for example, questioning, quizzes or buzz groups imply active involvement and participation. Quizzes and MCQ-testing can provide a formative 'check-up' on learning and point to gaps in understanding for the teachers and the participants. Spacing a course with intervening assignments can enable the transfer of skills to practice.


Subject(s)
Education, Medical, Graduate , Pediatrics/education , Clinical Competence , Educational Measurement , Humans , Learning , Neurology/education , Preceptorship , Teaching/methods , Teaching Materials
SELECTION OF CITATIONS
SEARCH DETAIL